… extended spectrum β-lactamase (ESBL) producing gram negative bacilli are becoming a
growing problem worldwide with difficulties in designing a national formulary for empirical …

… So, the current pattern of use of the beta lactams as an empirical therapy for most of the
common indications in a developing country like India, does not seem to be justified. …

… In conclusion, empirical therapy with non-carbapenems is an effective method by which
to reduce the risk of development of carbapenem-resistant organisms in patients with UTIs …

… tumours or haematological malignancies and treated with intravenous antipseudomonal
β-lactams for initial empiric therapy. Protocol was registered with PROSPERO ID 42016043377. …

… b-lactamase-producing Enterobacteriaceae has seriously reduced the number of empirical
… when choosing adequate initial therapy; increased reliance on the carbapenem class as …

… ), Enterobacteriaceae producing extended-spectrum b-lactamases, and multidrug-resistant …
anti-Gram-negative agents (b-lactams and fluoroquinolones) and the circulation of strains …

… the relevance of the adequacy of empirical therapy is limited. … to some antimicrobials as
beta-lactam/beta-lactam inhibitors, … of adequacy of empirical antibiotic therapy in mortality in a …

… showed higher mortality with empiric use of drugs other … empiric treatment when coverage
of ESBL-E is needed. The objective of this study was to assess the impact of empiric therapy …

… therapies were classified as empirical and definitive. Empirical therapy was defined as the
antimicrobial therapy … definitive therapy was defined as the adjusted antimicrobial therapy …

… not) be empirically treated with … therapy within <24 h. Apparently, patient records with
microbiology results were either not consulted or neglected before initiation of empirical therapy. …